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Purpose: To prospectively evaluate the safety, hypotensive effect, and preservation of visual 
fields of dorzolamide when added to latanoprost.
Subjects and methods: This study included 46 patients (46 eyes) with primary open-angle 
glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, 
and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The 
mean deviation shown by Humphrey perimetry was compared before and after twelve months 
of treatment. Adverse reactions were monitored over the 12-month study period.
Results: The mean baseline IOP was 17.2 ± 3.0 mmHg while those after 3, 6 and 12 months 
of treatment were 14.9 ± 3.0 mmHg, 14.5 ± 3.2 mmHg, and 14.6 ± 2.6 mmHg respectively 
(P , 0.0001, 1-β(power) = 0.9999571). The absolute reduction of IOP and the percent reduction 
were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry 
was similar before and after twelve months of treatment. Three patients discontinued dorzolamide 
therapy due to elevation of IOP and one patient discontinued it because of adverse reactions.
Conclusion: Dorzolamide is safe and effective when used for twelve months as add-on therapy 
to latanoprost for open-angle glaucoma.
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Introduction
Prostaglandin analog acts by enhancing the uveoscleral outflow and lowering the 
intraocular pressure (IOP). The significant effect on reducing IOP and the convenience 
of once daily administration made Prostaglandin analog eye drops the first line therapy 
for glaucoma for many ophthalmologists.1 If the reduction of IOP is insufficient, however, 
switching therapy or adding a new agent is needed.2 β-blockers or carbonic anhydrase 
inhibitors that inhibit aqueous humor production may be considered as second-line 
agents to be added on, since they have different mechanisms of reducing IOP to pros-
taglandin analog. Use of β-blockers in Japan started about 40 years ago when timolol 
maleate eye drops became available. As for carbonic anhydrase inhibitors, dorzolamide 
(0.5% and 1%) was introduced in 1999 and brinzolamide (1%) was released in 2002.3–5 
It has been reported that the effect of β-blockers and carbonic anhydrase inhibitors on 
IOP is comparable, when added to prostaglandin analog therapy.5–7 β-blockers can have 
systemic adverse effects, however, including induction of asthmatic attack, bradycardia, 
and depressive symptoms, making it difficult to use these medications in patients with 
such conditions or in the elderly whose physiological functions are impaired compared 
with younger individuals. In this respect, carbonic anhydrase inhibitors may have a Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
394
Inoue et al
better safety profile with fewer systemic adverse effects when 
added to prostaglandin analog therapy.
In previous studies on the IOP-lowering effect of dor-
zolamide when added to prostaglandin analog therapy, the 
percent reduction of IOP was reported to be 6.3%–24.0%.4–11 
Because dorzolamide is used as a 2% formulation in coun-
tries other than Japan,6–10 only a few reports have studied the 
1% formulation that is available there.3–5,11 In addition, the 
duration of treatment in those studies was short (four weeks,4 
three months,5 and six months11).
We previously reported on the IOP-lowering effect and 
safety of 1% dorzolamide when added to a prostaglandin 
analog for six months in patients with primary open-angle 
glaucoma.11 In the present study, the observation period was 
extended to twelve months and the effect of dorzolamide on 
preservation of the visual fields was also evaluated.
Subjects and methods
This was a prospective, multicenter open-label study. The 
study included 46 patients (22 men and 24 women) with 
46 eyes being treated for primary open-angle glaucoma. 
They were on treatment with latanoprost alone, and dorzol-
amide was added during the period between June 2008 and 
May 2009 at Inouye Eye Hospital or 13 other participating 
  institutions. The mean age ± Standard Deviation (SD) (range) 
of the patients was 69.5 ± 10.5 years (range: 43–87 years). 
The cases with the mean deviation (MD) value of −24.00 dB 
and below were excluded from the study. The MD obtained 
by Humphrey perimetry was −9.0 ± 5.6 dB (−20.05 to 
−0.63 dB) at baseline and the baseline IOP was 17.2 ± 3.0 
(12 to 25) mmHg. The spherical equivalent was −0.5 ± 3.9 
(+3.25 to −12.5) D.
In patients with glaucoma affecting both eyes, the eye 
with the higher IOP was evaluated. If both eyes had the same 
IOP, the right eye was evaluated.
When the chief physician judged an intraocular pressure 
drop effect was insufficient, once-daily administration (at 
night) of latanoprost was continued and 1% dorzolamide 
(three times daily [tid], morning, noon and night) was added. 
The IOP was measured by Goldmann applanation tonometry 
by the same observer at approximately the same time of day 
in each patient at baseline and every one to two months after 
starting the administration of dorzolamide. The baseline IOP 
was compared with that after 3, 6, and 12 months by analysis 
of variance (ANOVA) with the Bonferroni/Dunnett tests. The 
reduction of IOP and the percent decrease of IOP relative to 
baseline after 3, 6, and 12 months were calculated and com-
pared with Friedman’s test. The Humphrey C-30-2 Swedish 
Interactive Threshold Algorithm (SITA) Standard program 
was performed at baseline and after twelve months, and the 
MD values were compared by the paired t-test. Reliability 
visual field test results ,20% fixation errors, ,33% false-
positive results, and ,33% false-negative results. Adverse 
reactions were evaluated at every visit to hospital. Patients 
who did not present to hospital for follow-up, who discon-
tinued dorzolamide treatment, who started a new agent, or 
who underwent surgery during the 12-month study period 
were excluded from analysis of the IOP data. Differences 
were considered statistically significant at P , 0.05 for all 
comparisons. The present study was approved by the ethical 
committee of Inouye Eye Hospital. The purpose and proce-
dures of the study were explained to the patients and written 
informed consent was obtained from each subject.
Results
Compared with the baseline IOP (17.2 ± 3.0 mmHg), 
there was a significant decrease after 3, 6, and 12 months 
(14.9 ± 3.0 mmHg, 14.5 ± 3.2 mmHg, and 14.6 ± 2.6 mmHg, 
respectively) in the 46 subjects (P  , 0.0001, 1-β 
(power) = 0.9999571) (Figure 1).
The absolute reduction of IOP was similar after 3, 
6, and 12 months (2.4 ± 2.5 mmHg, 2.7 ± 2.4 mmHg, 
2.7 ± 2.6 mmHg, respectively). Likewise, the percent 
reduction of IOP was similar after 3, 6, and 12 months 
(13.0 ± 13.4%, 15.1 ± 13.5%, 14.6 ± 12.4%, respectively).
There was no difference of the MD obtained by   Humphrey 
perimetry at baseline and after 12 months of treatment 
(−9.0 ± 5.6 dB and −9.3 ± 5.5 dB, respectively) (Figure 2).
During the 12-month period of dorzolamide adminis-
tration, eleven patients (23.9%) dropped out of the study. 
Three patients were lost to follow-up, one patient moved 
and switched to another hospital, one patient suffered from 
adverse effects (ocular irritation), three patients did not 
achieve a sufficient reduction of IOP, one patient died of an 
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Figure 1 Intraocular pressure (IOP) before and after addition of dorzolamide.
Notes: *P , 0.0001, AnOVA and the Bonferroni/Dunnett tests.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
395
Efficacy of dorzolamide
unrelated disease, one patient underwent surgery for another 
disease, and one patient was enrolled in another study. The 
adverse effects observed in one patient resolved after discon-
tinuation of dorzolamide. Of the three patients who did not 
achieve a sufficient reduction of IOP, one patient increased 
IOP from 18 mmHg at baseline to 22 mmHg after two months 
and one patient increased IOP from 13 mmHg at baseline to 
14 mmHg after five months. In these two patients, dorzol-
amide was switched to a β-blocker. In the third patient, IOP 
increased from 19 mmHg at baseline to 22 mmHg after three 
months and glaucoma surgery was performed.
Discussion
Several studies have demonstrated that IOP is reduced 
when dorzolamide is added to basal prostaglandin analog 
therapy4–11 (Table 1).
In Japan, 0.5% and 1% formulations of dorzolamide 
are used, but only three studies have evaluated the effect of 
these formulations when added to basal prostaglandin ana-
log therapy.4,5,11 In the study by Maruyama and Shirato, 1% 
dorzolamide (tid) was added for three months   following three 
months of monotherapy with latanoprost in 33 patients with 
primary open-angle glaucoma.5 IOP decreased   significantly 
from baseline (16.0 ± 2.1 mmHg), with an absolute 
reduction and percent reduction of 1.0 mmHg and 6.3%, 
  respectively. In addition, Nakamura et al added 1% dorzol-
amide (twice daily [bid] or tid) for four weeks in 20 patients 
with   primary open-angle glaucoma, ocular hypertension, 
or angle-closure glaucoma after laser peripheral iridotomy 
who had been treated with latanoprost alone, but still had 
an IOP $ 18 mmHg.4 Measurement of the circadian changes 
of IOP showed a significant decrease from baseline 
(20.0 mmHg) at all time points, with the absolute reduction 
and percent reduction being 2.4 to 4.8 mmHg and 12.0 to 
24.0%, respectively. In our previous study, 1% dorzolamide 
(tid) was added to latanoprost or travoprost for six months 
in 55 patients with primary open-angle glaucoma.11 The IOP 
decreased significantly from baseline (16.7 ± 2.4 mmHg), 
and showed an absolute reduction and percent reduction 
of 2.5 to 2.8 mmHg and 14.2 to 16.4%, respectively. In the 
present study, 1% dorzolamide (tid) was added to latanoprost 
for twelve months in 46 patients with primary open-angle 
glaucoma. We found that the IOP decreased significantly 
from baseline (17.2 ± 3.0 mmHg), with the absolute reduc-
tion and percent reduction being 2.4 to 2.7 mmHg and 13.0 
to 15.1%, respectively. These results were consistent with 
those reported previously.4–11 However, the present study 
was conducted in an open-label manner, so the IOP-lowering 
effect of dorzolamide may have been overrated. When the 
percent reduction of IOP was compared between different 
formulations of dorzolamide, the IOP lowering effect of the 
2% formulation (12.5%–20.6%)6–10 and the 1% formulation 
(6.3%–24.0%)4,5,11 seemed to be similar.
No previous study has evaluated the effect of dorzolamide 
on preservation of the visual fields when added to basal 
prostaglandin analog therapy, possibly because the duration 
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Figure 2 Mean deviation at baseline and 12 months after addition of dorzolamide.
Note: Paired t-test.
Abbreviation: ns, not significant.
Table 1 review of previous studies conducted outside/inside Japan
Previous  
eye drops
Dorzolamide Number  
of cases
Duration Baseline IOP  
(mmHg)
Absolute  
reduction (mmHg)
Percent  
reduction (%)
O’Connor6 Latanoprost 2% (bid or tid) 25 1 year 19.8 3.9 19.7
Tamer7 Latanoprost 2% (bid) 36 4 weeks 19.9–23.3 2.6–3.2 12.5–14.7
Bournias8 Latanoprost 
Travoprost 
Bimatoprost
2% (tid) 40 4 months 20.3–21.9 2.8–3.4 13.3–15.5
Boyer9 Travoprost 2% (bid) 86 6 months 18.9 ± 4.2 3.9 20.6
Arici10 Latanoprost 2% (tid) 15 10 days 18.7 ± 2.3 2.8 15.0
Maruyama5 Latanoprost 1% (tid) 33 3 months 16.0 ± 2.1 1.0 6.3
nakamura4 Latanopropt 1% (bid or tid) 20 4 weeks 20.0 2.4–4.8 12.0–24.0
Inoue11 Latanoprost 
Travoprost
1% 55 6 months 16.7 ± 2.4 2.5–2.8 14.2–16.4
Abbreviations: bid, twice daily; tid, three times daily; IOP, intraocular pressure.Clinical Ophthalmology
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of combined treatment with dorzolamide was short in most 
studies. In a previous 1-year study, the effect of dorzolamide 
on the visual fields was not assessed because the study was 
conducted retrospectively.6 In the present study, the MD 
obtained by Humphrey perimetry did not change after addi-
tion of dorzolamide for 12 months, indicating a positive effect 
of dorzolamide therapy on preservation of the visual fields. 
However, the treatment period was only twelve months, so 
further studies over a longer period are needed.
When dorzolamide is used with a prostaglandin analog, 
the reported adverse effects include hyperemia, irritation, 
foreign body sensation, blurred vision, corneal epithelial 
disorder, and dysgeusia.4,5,7,8,10 In several previous studies, 
no serious adverse effects were observed,4,5,7–11 which is 
consistent with the present results. In the present study, 
sufficient reduction of IOP was not achieved by combined 
therapy in three patients, suggesting that there is a group of 
non-responders to dorzolamide.
Conclusion
Dorzolamide had a potent IOP-lowering effect as well as a 
positive effect on preservation of the visual fields in patients 
with primary open-angle glaucoma when added to latanoprost 
for twelve months. However, it remains unclear whether these 
effects are caused by adding dorzolamide or they can be 
gained by latanoprost only, or they are synergetic effects of 
both dorzolamide and latanoprost. It also had a good safety 
profile and did not cause any serious adverse effects. Thus, 
the 1% dorzolamide has enough IOP-lowering effect and it 
may be a useful second-line agent after latanoprost for the 
treatment of glaucoma.
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